FDA Inspection 1125738 — Novartis Pharmaceuticals Corporation
The FDA completed an inspection of Novartis Pharmaceuticals Corporation on July 2, 2020 in East Hanover, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- July 2, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- East Hanover, NJ (United States)
Additional Details
Sponsor, Contract Research Organization